|
|
|
|
|
|
Sponsored by: |
Angiotech Pharmaceuticals |
Information provided by: | Angiotech Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00288418 |
The main purpose of this study is to determine if the Angiotech central venous catheter (CVC) is equal in effectiveness to a CVC coated with chlorhexidine and silver sulfadiazine in preventing bacterial catheter colonization. Other objectives of this study are to determine if the Angiotech CVC is equal in effectiveness to a CVC coated with chlorhexidine and silver sulfadiazine in preventing catheter-related local infection, and catheter-related bloodstream infection. This study will also assess the safety of the Angiotech CVC.
Condition | Intervention | Phase |
Bacterial Infections |
Device: Central Venous Catheter |
Phase III |
MedlinePlus related topics: | Bacterial Infections |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Single Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Controlled, Randomized, Single-Blind, Multi-Center Pivotal Clinical Study Using Angiotech CVC to Prevent Bacterial Colonization on Short-Term Central Venous Catheters |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Show 21 Study Locations |
Angiotech Pharmaceuticals |
Study ID Numbers: | 011-ACVC05 |
First Received: | February 6, 2006 |
Last Updated: | July 13, 2007 |
ClinicalTrials.gov Identifier: | NCT00288418 |
Health Authority: | United States: Food and Drug Administration |
|
|
|